Summary
4.30 -0.21(-4.66%)09/20/2024
Ironwood Pharmaceuticals Inc (IRWD)
Ironwood Pharmaceuticals Inc (IRWD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -5.05 | -5.91 | -10.14 | -22.73 | -52.80 | -53.16 | -54.59 | -55.93 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.30 | |
| Open | 4.49 | |
| High | 4.58 | |
| Low | 4.29 | |
| Volume | 1,993,786 | |
| Change | -0.23 | |
| Change % | -5.05 | |
| Avg Volume (20 Days) | 1,519,931 | |
| Volume/Avg Volume (20 Days) Ratio | 1.31 | |
| 52 Week Range | 3.79 - 15.70 | |
| Price vs 52 Week High | -72.61% | |
| Price vs 52 Week Low | 13.46% | |
| Range | -4.23 | |
| Gap Up/Down | -0.26 | |
Fundamentals | ||
| Market Capitalization (Mln) | 720 | |
| EBIDTA | 121,498,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.2600 | |
| WallStreet Target Price | 16.83 | |
| Book Value | -2.0790 | |
| Earnings Per Share | -6.7800 | |
| EPS Estimate Current Quarter | 0.1900 | |
| EPS Estimate Next Quarter | 0.2000 | |
| EPS Estimate Current Year | 0.6000 | |
| EPS Estimate Next Year | 0.7500 | |
| Diluted EPS (TTM) | -6.7800 | |
| Revenues | ||
| Profit Marging | -2.5441 | |
| Operating Marging (TTM) | 0.1530 | |
| Return on asset (TTM) | 0.0939 | |
| Return on equity (TTM) | -5.7472 | |
| Revenue TTM | 413,551,008 | |
| Revenue per share TTM | 2.6470 | |
| Quarterly Revenue Growth (YOY) | -0.2800 | |
| Quarterly Earnings Growth (YOY) | -0.6850 | |
| Gross Profit (TTM) | 366,331,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 12.3305 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.5899 | |
| Revenue Enterprise Value | 4.1940 | |
| EBITDA Enterprise Value | -2.0077 | |
| Shares | ||
| Shares Outstanding | 158,956,992 | |
| Shares Float | 139,995,128 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.25 | |
| Insider (%) | 1.73 | |
| Institutions (%) | 100.98 | |
08/09 12:10 EST - seekingalpha.com
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2024 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Andrew Davis - Chief Business Officer Conference Call Participants David Amsellem - Piper Sandler Amy Li - Jefferies Mohit Bansal - Wells Fargo Jason Butler - Citizens JMP Tim Chiang - Capital One Operator Thank you for standing by. My name, Celine, and I will be your conference operator today.
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2024 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Andrew Davis - Chief Business Officer Conference Call Participants David Amsellem - Piper Sandler Amy Li - Jefferies Mohit Bansal - Wells Fargo Jason Butler - Citizens JMP Tim Chiang - Capital One Operator Thank you for standing by. My name, Celine, and I will be your conference operator today.
08/09 12:00 EST - zacks.com
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates.
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates.
08/08 09:17 EST - zacks.com
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.17. This compares to earnings of $0.31 per share a year ago.
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.17. This compares to earnings of $0.31 per share a year ago.
08/01 11:06 EST - zacks.com
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/23 07:25 EST - zacks.com
New Strong Sell Stocks for July 23rd
ALK, DINO and IRWD have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2024.
New Strong Sell Stocks for July 23rd
ALK, DINO and IRWD have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2024.
07/05 08:06 EST - zacks.com
New Strong Sell Stocks for July 5th
ARCO, IRWD and AVT have been added to the Zacks Rank #5 (Strong Sell) List on July 5, 2024.
New Strong Sell Stocks for July 5th
ARCO, IRWD and AVT have been added to the Zacks Rank #5 (Strong Sell) List on July 5, 2024.
06/28 11:00 EST - accesswire.com
The Schall Law Firm Starts Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Begin Conversation
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Starts Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Begin Conversation
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/26 15:30 EST - accesswire.com
The Schall Law Firm Initiates Inquiry Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Incurred Losses To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Inquiry Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Incurred Losses To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/25 14:45 EST - accesswire.com
The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Suffered Losses To Initiate Contact
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Suffered Losses To Initiate Contact
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/24 16:45 EST - accesswire.com
The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Establish Communication
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Establish Communication
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/23 11:00 EST - accesswire.com
The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors With Losses To Connect
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors With Losses To Connect
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/22 11:00 EST - accesswire.com
The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/20 13:00 EST - seekingalpha.com
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032. NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with short bowel syndrome who are dependent on parenteral support.
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032. NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with short bowel syndrome who are dependent on parenteral support.
06/19 16:20 EST - accesswire.com
Allegations Against Ironwood Pharmaceuticals Inc The Schall Law Firm Initiates Probe And Urges Investors With Losses To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Allegations Against Ironwood Pharmaceuticals Inc The Schall Law Firm Initiates Probe And Urges Investors With Losses To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/18 16:00 EST - accesswire.com
Claims Against Ironwood Pharmaceuticals Inc The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Claims Against Ironwood Pharmaceuticals Inc The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/11 19:00 EST - accesswire.com
Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/09 11:00 EST - accesswire.com
Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Urges Investors With Losses To Contact Them
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Urges Investors With Losses To Contact Them
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.